Imunon, Inc. Approves Executive Stock‑Pay Programs for Officers

What Happened
Imunon, Inc. filed an 8-K (Aug 11, 2026) reporting that its Compensation Committee and Board approved programs allowing certain executive officers to elect to receive a portion of their base salary in shares of common stock and to receive additional bonus shares tied to those elections. Affected officers and election limits: Stacy Lindborg (President & CEO) up to 50% of base salary, Michael Tardugno (Executive Chairman) up to 100%, and Douglas Faller (Chief Medical Officer) up to 40%.

Key Details

• Stacy Lindborg: may take up to 50% of base salary in shares; additional shares generally equal 12% of the net stock payment, amended to 35% for shares issuable on August 14, 2026 and 17.5% for pay dates beginning Aug 28 through Sep 25, 2026.
• Michael Tardugno: may take up to 100% of base salary in shares; additional shares: 20% for July 31, 40% for August 14, and 20% for each pay date Aug 28–Sep 25, 2026.
• Douglas Faller: may take up to 40% of base salary in shares; bonus shares generally 12% of the net stock payment, amended to 15% for pay dates beginning July 31 through Sep 25, 2026; Faller’s shares will be issued under Imunon’s 2018 Stock Incentive Plan.
• Shares issuable to Lindborg and Tardugno were treated as exempt from registration under Section 4(a)(2) of the Securities Act (not a public offering).

Why It Matters
This action changes how select executives may be paid, shifting some compensation from cash to equity and adding bonus shares tied to those elections. For investors, equity-based pay can reduce near-term cash outflows for the company and align management incentives with shareholder value, but it may also increase share count (dilution) over the covered pay dates (late July through September 2026). The filing also notes that the issuances to two executives were treated as private, unregistered transactions while the third uses the company’s stock plan.